We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fast-Acting Nasal Spray Reverses Opioid Overdose

By HospiMedica International staff writers
Posted on 01 Dec 2015
A nasal spray formulation of naloxone acts as a swift reversal agent for emergency treatment of opioid overdose. More...


A product of Adapt Pharma (Radnor, PA, USA), The Narcan nasal spray device delivers a 4 mg dose of naloxone hydrochloride in a single 0.1 ml aerosol spray, preferably while the patient is lying on his or her back. It is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system (CNS) depression. Clinical trials have demonstrated that when used as directed, blood levels of naloxone are similar to those achieved with naloxone injectors.

The ready-to-use, needle-free device requires no assembly or priming prior to use, and can be administered in an emergency by family members, caregivers, or others to reverse the effects of opioid overdose until help arrives. Since an opioid overdose may cause brain damage or death, Narcan should be administered as quickly as possible if a patient is unresponsive and an opioid overdose is suspected, even when in doubt. If the desired response is not obtained after 2 or 3 minutes, an additional dose of Narcan nasal spray should be administered.

“Opioid overdose is responsible for the deaths of thousands of Americans in communities throughout the country, leaving a trail of devastation for friends and families,” said Seamus Mulligan, Chairman and CEO of Adapt Pharma. “This new device makes naloxone readily available for emergency use by a friend, family member or caregiver, as well as offering an alternative treatment option for first responders and healthcare providers. It gives new hope to those concerned about the potentially fatal effects of opioid overdose.”

“Combating the opioid abuse epidemic is a top priority for the FDA; we cannot stand by while Americans are dying. Use of the nasal spray requires no special training and it is an important new alternative for family members,” said acting FDA Commissioner Stephen Ostroff, MD. “While naloxone will not solve the underlying problems of the opioid epidemic, we are speeding to review new formulations that will ultimately save lives that might otherwise be lost to drug addiction and overdose.”

Naloxone is used to counter the effects of opioid overdose, for example heroin or morphine, and is specifically used to counteract life-threatening depression of the CNS and respiratory system. It has been used for more than 40 years for reversal of respiratory depression due to opioid overdose, but has been primarily used by emergency medical services (EMS) in injection form.

Related Links:

Adapt Pharma



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Glucose Meter
StatStrip®
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.